Carbohydrates are polyhydroxylated compounds that when incorporated onto a small molecule may be used as a platform from which to modulate physicochemical and biopharmaceutical properties of the resulting compounds for medicinal chemistry applications [1] [2] [3] [4] . Carbohydrates linked to natural product based drugs are often a prerequisite for biological activity and heavily influence the pharmacokinetics, drug targeting and mechanism of action [5] . The development of synthetic carbohydrate-based small molecules is increasingly being recognized as a viable and appealing approach towards safe and effective therapeutics [1] [2] [3] [4] 6] and ester prodrugs of monosaccharides have been developed [7] [8] [9] . Esters are the most common prodrug moiety employed by the pharmaceutical industry [10] . They are used extensively to mask polar hydroxyl groups with hydrophobic acyl groups to enhance passive diffusion and enable therapeutic concentrations of the prodrug to reach the bloodstream. The ester functional group is susceptible to in vivo hydrolysis by hydrolytic plasma enzymes and cellular carboxylesterase (CE) enzymes to generate the corresponding alcohol and carboxylate [11, 12] . Human CEs play a key role in fatty acid metabolism, they comprise a number of isozymes with differential distribution, expression profile and ester substrate specificity and they differ to plasma esterase enzymes [10] . The heterogeneity of substrate specificity of ester hydrolysis enzymes means that it is difficult to predict activity on differing acyl groups on parent alcohol drugs and this limits rational drug optimization [13] . Yarema and colleagues investigated the bioactivity of N-acetyl-Dmannosamine (ManNAc) and butyrate and showed that in isolation each component had poor drug-like properties however when combined into a single carbohydrate molecule (Bu 4 ManNAc) exhibited favourable biopharmaceutical properties [14, 15] .
In this paper we describe the synthesis of novel glycoconjugates wherein the carbohydrate moiety is peracylated with acyl groups comprising acetyl, propionyl, butanoyl, pentanoyl (valeryl) or 3-methylbutanoyl (isovaleryl) groups. The in vitro metabolic stability, plasma stability and plasma protein binding were measured for one set of the glycoconjugates to establish the impact of the different acyl groups on these biopharmaceutical properties. To the best of our knowledge there has been no systematic approach in the medicinal chemistry of glycoconjugate small molecules to address the effect of labile acyl groups on biopharmaceutical properties associated with carbohydrate ester hydrolysis. As a consequence we were keen to provide new chemical tools in this context.
Copper-catalysed azide-alkyne cycloaddition (CuAAC) with carbohydrate-based azide substrates is now routinely applied in drug discovery and has proven extremely versatile both in the preparation of glycoconjugate small molecule inhibitors against a range of enzymes and to append carbohydrates to biomolecules [16] [17] [18] . Several reactions fulfil the criteria that defines click chemistry [19] , however it is CuAAC to regioselectively form 1,2,3-triazoles that has proven the most accomplished click chemistry reaction for the development of new molecules with useful chemical properties, delivering an impressive volume of diverse applications within a short period [20] . In drug development some functional groups, while synthetically attractive, can be a liability to biopharmaceutical performance of a compound in vivo. The early applications of glycopyranosyl azide building blocks in click chemistry demonstrated that the formed triazole was compatible with commonly employed carbohydrate protecting group approaches [21] and that peracetylated glycopyranosyl triazoles were robust molecules [21, 22] . Glycopyranosyl azides are stable and are inert towards a wide range of reaction conditions and are readily synthesised anomerically pure [16] . In addition a range of bioactive glycopyranosyl triazoles have been reported [4, 6, 17, [22] [23] [24] [25] . glucose with propionic anhydride and butyric anhydride in either refluxing pyridine or using sodium propanoate or sodium butanoate, respectively, generated an anomeric mixture of the peracylated sugars 11 and 12, Scheme 1 [26] [27] [28] . While the target β-anomer predominated (typical ratio β: ~80:20) it could not be readily separated from the -anomer by chromatography or crystallization. We continued with compounds 11 and 12 as anomeric mixtures and successfully converted the β-anomer to azides 2 and 3 (the -anomer is unreactive), Scheme 1, extensive chromatography was however required for purification. The second approach employed peracetylated β-glycopyranosyl azides 1 and 6 as indirect precursors for the remaining target azides 2-5 and 7-10, Scheme 2. Deprotection of 1 and 6 using Zemplén conditions gave the β-glycopyranosyl azides 13 and 14, respectively, in an almost quantitative yield [29] . Next acylation of 13 and 14 with the corresponding propionic, butyric, pentanoic or 3-methyl butyric acid anhydride in pyridine gave the target per-O-acylated β-glycopyranosyl azides 2-5 and 7-10 in good to high yields. This second approach was preferred to the first as it provided good yields from accessible starting materials and circumvented the purification difficulty caused by the formation and use of anomeric mixtures. The 1 H and 13 C NMR spectra of azide compounds 2-5 and 7-10 were consistent with their expected structures. propionyl, butanoyl, pentanoyl and 3-methylbutanoyl acyl groups.
With the panel of anomeric glycopyranosyl azides 1-10 in hand next the 1,4-disubstituted- In order to assess the susceptibility of these compounds to ester hydrolysis within plasma, we determined the in vitro stability of compounds 25 and 15-19 in human plasma at 37 °C, Table 1 .
The pentanoyl (18) and 3-methylbutanoyl (19) esters, together with the corresponding fully deacylated compound 25 were stable in human plasma. In contrast, the shorter chain acetyl, propionyl and butanoyl analogues (15, 16 and 17) degraded with estimated half lives of 55, 26, and 555 min, respectively, the order of stability is butanoyl > acetyl > propionyl. Multiple mono-, di-and tri-acylated hydrolysis products as well as the fully hydrolysed compound 25 were detected for each labile compound consistent with serial hydrolysis of the ester moieties.
Given the broad range of calculated Log P (cLog P) values for the acylated glycoconjugates (+2.25 to +8.60, [31] .
HSA binding increased with increasing size and lipophilicity of the acyl group and the two most highly bound compounds (18 and 19) were also the most stable in human plasma, Table 1 . On this basis it seems likely that the relative plasma stability of the different esters is determined by a combination of the intrinsic susceptibility to hydrolytic enzymes and the extent of binding to plasma proteins. Noncovalent plasma protein binding may be a desirable characteristic for diagnostic molecules such as MRI contrast agents, to increase the blood circulation half-life [32] .
In addition it has been demonstrated that plasma protein binding often has little clinical relevance on drug exposure [33] .
We next determined the in vitro stability of the compounds 25 and 15-19 in human liver microsomes (HLMs) to provide a preliminary indication of the likely in vivo hepatic metabolic clearance and to see if metabolic products corresponding to loss of the acyl groups, including complete loss (compound 25) could be detected. Microsomal stability was assessed in both the presence and absence of NADPH, the cofactor required for oxidative activity of the cytochrome P450 (CYP450) enzyme family. This allowed a qualitative indication of the relative contributions of CYP450 and non-CYP450 mediated degradation processes. The pentanoyl (18) and 3-methylbutanoyl (19) compounds, together with compound 25, were essentially stable in HLMs in both the presence and absence of NADPH; these compounds would therefore be expected to be subject to low hepatic metabolic clearance in vivo. In contrast, the acetyl, propionyl and butanoyl analogues (15, 16 and 17) were degraded in HLMs in the presence of NADPH, and a comparable degradation rate for each compound in the absence of NADPH was evident, an indicator that microsomal metabolism was primarily due to non-CYP450 enzymes. Mono-, di-and tri-acylated hydrolysis products as well as the fully hydrolysed compound 25 were detected for each of the labile acyl derivatives, an indicator that the cofactor-independent degradation resulted from compound susceptibility to hydrolytic enzymes such as microsomal esterases.
Log P describes compound lipophilicity, and values often correlate with a number of key biopharmaceutical parameters in drug discovery. The use of software tools to calculate Log P (cLog P) is routine to provide rapid and accurate predictions when used with an awareness of limitations of the software [10, 34] . Table 1 contains calculated Log P (cLog P) values and molecular weight for glycoconjugates 15-19 and 25. The trend of cLogP values is consistent with the compounds biopharmaceutical properties, discussed above. cLogP values increase with the size of the acyl group, it is feasible that the different esters could also be applied to balance oral absorption and bioavailability characteristics of prodrugs with esterase processing. Supporting Information. Experimental details for synthetic procedures and biological methods, 1 H and 13 C NMR spectra of new compounds.
